Clinical Trials of Oncolytic Viruses in Breast Cancer

Breast cancer is the second most common kind of cancer worldwide and oncolytic viruses may offer a new treatment approach. There are three different types of oncolytic viruses used in clinical trials; (i) oncolytic viruses with natural anti-neoplastic properties; (ii) oncolytic viruses designed for...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 11; p. 803050
Main Authors Carter, Mary E, Koch, André, Lauer, Ulrich M, Hartkopf, Andreas D
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 23.12.2021
Subjects
breast cancer
clinical trials
Oncology
oncolytic virus
review
virotherapy
breast cancer
clinical trials
virotherapy
oncolytic virus
review
Online AccessGet full text

Cover

Abstract Breast cancer is the second most common kind of cancer worldwide and oncolytic viruses may offer a new treatment approach. There are three different types of oncolytic viruses used in clinical trials; (i) oncolytic viruses with natural anti-neoplastic properties; (ii) oncolytic viruses designed for tumor-selective replication; (iii) oncolytic viruses modified to activate the immune system. Currently, fourteen different oncolytic viruses have been investigated in eighteen published clinical trials. These trials demonstrate that oncolytic viruses are well tolerated and safe for use in patients and display clinical activity. However, these trials mainly studied a small number of patients with different advanced tumors including some with breast cancer. Future trials should focus on breast cancer and investigate optimal routes of administration, occurrence of neutralizing antibodies, viral gene expression, combinations with other antineoplastic therapies, and identify subtypes that are particularly suitable for oncolytic virotherapy.
AbstractList Breast cancer is the second most common kind of cancer worldwide and oncolytic viruses may offer a new treatment approach. There are three different types of oncolytic viruses used in clinical trials; (i) oncolytic viruses with natural anti-neoplastic properties; (ii) oncolytic viruses designed for tumor-selective replication; (iii) oncolytic viruses modified to activate the immune system. Currently, fourteen different oncolytic viruses have been investigated in eighteen published clinical trials. These trials demonstrate that oncolytic viruses are well tolerated and safe for use in patients and display clinical activity. However, these trials mainly studied a small number of patients with different advanced tumors including some with breast cancer. Future trials should focus on breast cancer and investigate optimal routes of administration, occurrence of neutralizing antibodies, viral gene expression, combinations with other antineoplastic therapies, and identify subtypes that are particularly suitable for oncolytic virotherapy.
Author Hartkopf, Andreas D
Carter, Mary E
Lauer, Ulrich M
Koch, André
AuthorAffiliation 1 Department of Obstetrics and Gynaecology, University of Tuebingen , Tuebingen , Germany
2 Department of Internal Medicine VIII, Medical Oncology & Pneumology, University of Tuebingen , Tuebingen , Germany
AuthorAffiliation_xml – name: 2 Department of Internal Medicine VIII, Medical Oncology & Pneumology, University of Tuebingen , Tuebingen , Germany
– name: 1 Department of Obstetrics and Gynaecology, University of Tuebingen , Tuebingen , Germany
Author_xml – sequence: 1
  givenname: Mary E
  surname: Carter
  fullname: Carter, Mary E
  organization: Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany
– sequence: 2
  givenname: André
  surname: Koch
  fullname: Koch, André
  organization: Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany
– sequence: 3
  givenname: Ulrich M
  surname: Lauer
  fullname: Lauer, Ulrich M
  organization: Department of Internal Medicine VIII, Medical Oncology & Pneumology, University of Tuebingen, Tuebingen, Germany
– sequence: 4
  givenname: Andreas D
  surname: Hartkopf
  fullname: Hartkopf, Andreas D
  organization: Department of Obstetrics and Gynaecology, University of Tuebingen, Tuebingen, Germany
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35004328$$D View this record in MEDLINE/PubMed
BookMark eNpVkb1PHDEQxa2IKHyEPlW0Jc1dxp-7biLBKRAkJBoSpbO8Y5sY7dlg7yHx38fHEQTTeDR-7zcjvUOyl3LyhHyhsOR80N9CTrhkwOhyAA4SPpADxrhYaMH_7L3p98lxrXfQSkmgwD-RfS4BBGfDAZGrKaaIdupuSrRT7XLorhPm6WmO2P2OZVN97WLqzoq3de5WNqEvn8nH0MT--OU9Ir_Of9ysfi6uri8uV6dXCxSKzQtltXSWWyakF8yhdOi8VnwUI9VW6hHHYFmQDlBDGBQw19MwKh0osp45fkQud1yX7Z25L3Fty5PJNprnQS63xpZ26OQNNiNwL0aGIPogRoW20RxXrBdAbWN937HuN-PaO_RpLnZ6B33_k-Jfc5sfzdBzLrVugJMXQMkPG19ns44V_TTZ5POmGqboIKGtU00KOymWXGvx4XUNBbMNz2zDM9vwzC68Zvn69rxXw_-o-D-YVpfT
CitedBy_id crossref_primary_10_3390_cancers15082204
crossref_primary_10_3389_fimmu_2024_1375433
crossref_primary_10_1007_s12609_023_00492_4
crossref_primary_10_1186_s40164_022_00338_2
crossref_primary_10_3389_fcell_2023_1111796
crossref_primary_10_1007_s11912_022_01339_4
crossref_primary_10_3389_fonc_2023_1186888
crossref_primary_10_3389_fonc_2022_919072
crossref_primary_10_1142_S0218127423500621
crossref_primary_10_3390_md21020077
crossref_primary_10_1016_j_apsb_2024_03_007
crossref_primary_10_3390_v16040567
Cites_doi 10.1158/1078-0432.CCR-06-0759
10.1007/s10549-021-06423-0
10.1016/j.ymthe.2004.06.158
10.1007/s11523-018-0608-8
10.1245/ASO.2006.08.035
10.1038/sj.gt.3301885
10.1158/1078-0432.CCR-05-2038
10.1038/mt.2009.262
10.2217/fmb.12.4
10.3322/caac.21654
10.1038/nbt.2287
10.18632/oncotarget.2901
10.2217/fon.10.66
10.1158/1538-7445.Sabcs19-gs3-04
10.1080/2162402X.2015.1078057
10.1038/sj.gt.3302555
10.3390/cancers10050144
10.1007/s10549-017-4538-4
10.2174/1566523218666180910163805
10.1001/jamaoncol.2016.2064
10.1038/sj.cgt.7701080
10.1158/1078-0432.CCR-12-2546
10.1016/j.tim.2008.07.009
10.1158/1078-0432.CCR-0349-03
10.1016/S0140-6736(16)31891-8
10.1038/nrc948
10.1172/JCI9762
10.1038/mt.2014.194
10.1200/JCO.2014.58.3377
10.1038/sj.cgt.7701110
10.1038/nrc3770
10.1158/1078-0432.CCR-09-3167
10.1016/S0952-7915(99)80064-8
10.2967/jnumed.121.262485
10.6004/jnccn.2020.7554
10.1007/978-3-642-59421-2_16
10.1158/0008-5472.CAN-09-3567
10.1038/nrd4663
10.1200/JCO.2002.08.042
10.1055/s-0031-1298281
10.3390/v13061128
10.1002/ijc.26216
10.1016/j.tips.2007.05.005
10.1016/j.virusres.2014.02.016
10.1016/S1470-2045(20)30754-3
10.1016/S0140-6736(20)32531-9
10.18632/oncotarget.5116
10.20506/rst.19.2.1231
10.1056/NEJMoa1413513
10.1016/j.cell.2017.01.017
10.1038/nrc3239
10.1016/j.micinf.2006.10.019
10.1016/j.ygyno.2013.05.004
10.1038/sj.onc.1203251
10.1136/jitc-2020-001486
10.1126/science.1851332
10.1016/j.cell.2017.08.027
10.1158/2326-6066.CIR-14-0015
10.2174/156800907780058808
10.1002/jcp.27150
10.1099/0022-1317-83-12-2915
10.1007/s10637-015-0216-8
10.1056/NEJMoa1809615
10.1038/gt.2009.103
10.1007/s10637-009-9279-8
10.1038/gt.2008.179
10.1016/j.annonc.2021.05.801
10.1006/viro.1993.1602
10.1016/j.biochi.2007.03.001
10.1038/s41417-020-00265-6
10.1093/hmg/10.7.677
10.1038/cgt.2011.80
10.1056/NEJMoa1910549
10.1016/j.ygyno.2011.06.021
10.3332/ecancer.2020.1149
10.1080/2162402X.2020.1729300
10.1056/NEJMoa1903765
10.1006/mthe.2001.0318
10.1016/j.ccr.2005.06.009
10.2147/OV.S54780
10.1038/77558
10.1007/s10637-012-9865-z
10.1001/jamaoncol.2017.4445
10.1016/S1470-2045(13)70130-X
10.1186/s40364-021-00318-4
10.1159/000453569
10.1056/NEJMoa1810527
10.1136/jitc-2019-000465
10.1007/s40265-015-0522-7
10.1038/mt.2011.113
ContentType Journal Article
Copyright Copyright © 2021 Carter, Koch, Lauer and Hartkopf.
Copyright © 2021 Carter, Koch, Lauer and Hartkopf 2021 Carter, Koch, Lauer and Hartkopf
Copyright_xml – notice: Copyright © 2021 Carter, Koch, Lauer and Hartkopf.
– notice: Copyright © 2021 Carter, Koch, Lauer and Hartkopf 2021 Carter, Koch, Lauer and Hartkopf
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fonc.2021.803050
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2234-943X
EndPage 803050
ExternalDocumentID oai_doaj_org_article_c1fb03e4b2c047f4b6cad71d3627401a
10_3389_fonc_2021_803050
35004328
Genre Journal Article
Review
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
DIK
EBS
EJD
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
IPNFZ
KQ8
M48
M~E
NPM
OK1
PGMZT
RIG
RNS
RPM
AAYXX
CITATION
7X8
ITC
5PM
ID FETCH-LOGICAL-c462t-6a95da3a245e42dc5dcde963b4b19a59bcbfa2f5d0c90f8602d71fb69f1c272d3
IEDL.DBID RPM
ISSN 2234-943X
IngestDate Thu Jul 04 20:59:17 EDT 2024
Tue Sep 17 20:48:58 EDT 2024
Fri Aug 16 09:19:44 EDT 2024
Thu Sep 26 19:28:35 EDT 2024
Sat Sep 28 08:23:37 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords breast cancer
clinical trials
virotherapy
oncolytic virus
review
Language English
License Copyright © 2021 Carter, Koch, Lauer and Hartkopf.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c462t-6a95da3a245e42dc5dcde963b4b19a59bcbfa2f5d0c90f8602d71fb69f1c272d3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Breast Cancer, a section of the journal Frontiers in Oncology
Reviewed by: Masmudur Mohammed Rahman, Arizona State University, United States; Konstantin Kousoulas, Louisiana State University, United States; Robert Kratzke, University of Minnesota Twin Cities, United States
Edited by: Assia Konsoulova, Complex Oncological Center (Burgas), Bulgaria
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733599/
PMID 35004328
PQID 2618506276
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_c1fb03e4b2c047f4b6cad71d3627401a
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8733599
proquest_miscellaneous_2618506276
crossref_primary_10_3389_fonc_2021_803050
pubmed_primary_35004328
PublicationCentury 2000
PublicationDate 2021-12-23
PublicationDateYYYYMMDD 2021-12-23
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-23
  day: 23
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in oncology
PublicationTitleAlternate Front Oncol
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Pesonen (B49) 2012; 130
Alexander (B66) 2000; 19
Kaufman (B91) 2010; 6
Kwan (B92) 2021; 13
Swain (B6) 2015; 372
Macedo (B93) 2020; 8
Ribas (B24) 2017; 170
Liu (B84) 2005; 12
Shay (B80) 2001; 10
Nemunaitis (B81) 2000; 60
Pecora (B54) 2002; 20
Hartkopf (B94) 2013; 130
Gianni (B18) 2020; 80
Cerullo (B48) 2011; 19
Andtbacka (B37) 2015; 33
Hartkopf (B30) 2012; 72
Larson (B78) 2015; 6
Nokisalmi (B50) 2010; 16
Pardoll (B8) 2012; 12
Schmid (B16) 2018; 379
Lichty (B35) 2014; 14
Chopra (B7) 2018; 13
Hemminki (B46) 2015; 6
Kaufman (B36) 2015; 14
Chaurasiya (B27) 2020; 9
Zamarin (B64) 2012; 7
O’shea (B86) 2005; 8
Chaurasiya (B63) 2021; 28
Russell (B9) 2012; 30
Sung (B83) 2001; 3
Cerullo (B47) 2010; 70
Strong (B69) 1993; 197
O'bryan (B60) 2018; 18
Ganar (B65) 2014; 184
Bramante (B45) 2016; 5
Zeh (B40) 2015; 23
Ben-Aharon (B21) 2018; 4
Roberts (B72) 2008; 16
Wold (B82) 1999; 11
Burgert (B85) 2002
Kimata (B56) 2006; 13
Farwell (B29) 2021; 62
Stojdl (B67) 2000; 6
Binz (B11) 2015; 4
Russell (B39) 2007; 28
Chu (B76) 2004; 10
Morris (B42) 2013; 31
Nemunaitis (B53) 2007; 14
Laurie (B55) 2006; 12
Siegel (B2) 2021; 71
Sharma (B22) 2017; 168
Smith (B71) 2002; 83
Rojas (B79) 2009; 16
Keenan (B14) 2020; 18
Garza-Morales (B26) 2018; 10
Lawler (B33) 2017; 3
Sahin (B58) 2012; 19
Fueyo (B87) 2000; 19
Li (B52) 2008; 16
Chalikonda (B75) 2007; 15
Turner (B4) 2018; 379
Nemunaitis (B51) 2010; 18
Society (B1) 2017
Huang (B88) 2003; 63
Andrea Mccart (B73) 2004; 10
Swain (B3) 2013; 14
García (B90) 2007; 89
Antonio Chiocca (B31) 2002; 2
Arab (B61) 2019; 234
Chakrabarty (B68) 2015; 33
Gollamudi (B41) 2010; 28
Heise (B77) 2000; 105
Kanerva (B44) 2013; 19
Hartkopf (B10) 2011; 123
Martuza (B32) 1991; 252
Schmid (B19) 2020; 382
Hu (B59) 2006; 12
Ushijima (B70) 2007; 9
Martini (B62) 2020; 14
Hartkopf (B13) 2016; 11
Jin (B28) 2021; 9
Liu (B89) 2003; 10
Cortes (B17) 2020; 396
Nakao (B57) 2007; 7
Im (B5) 2019; 381
Torres (B23) 2021
Harbeck (B12) 2017; 389
Chiocca (B34) 2014; 2
Winer (B15) 2021; 22
Greig (B38) 2016; 76
Niavarani (B25) 2020; 8
Bernstein (B43) 2018; 167
Miles (B20) 2021; 32
Mccart (B74) 2001; 61
References_xml – volume: 12
  start-page: 6737
  year: 2006
  ident: B59
  article-title: A Phase I Study of OncoVEX GM-CSF, a Second-Generation Oncolytic Herpes Simplex Virus Expressing Granulocyte Macrophage Colony-Stimulating Factor
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-06-0759
  contributor:
    fullname: Hu
– year: 2021
  ident: B23
  article-title: Emerging Combination Immunotherapy Strategies for Breast Cancer: Dual Immune Checkpoint Modulation, Antibody-Drug Conjugates and Bispecific Antibodies
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-021-06423-0
  contributor:
    fullname: Torres
– volume: 10
  year: 2004
  ident: B73
  article-title: Oncolytic Vaccinia Virus Expressing the Human Somatostatin Receptor SSTR2: Molecular Imaging After Systemic Delivery Using 111in-Pentetreotide
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2004.06.158
  contributor:
    fullname: Andrea Mccart
– volume: 13
  year: 2018
  ident: B7
  article-title: Annual Congress of the European Society for Medical Oncology (ESMO): Munich, Germany, 19–23 October 2018
  publication-title: Targeted Oncol
  doi: 10.1007/s11523-018-0608-8
  contributor:
    fullname: Chopra
– volume: 13
  year: 2006
  ident: B56
  article-title: Pilot Study of Oncolytic Viral Therapy Using Mutant Herpes Simplex Virus (HF10) Against Recurrent Metastatic Breast Cancer
  publication-title: Ann Surg Oncol
  doi: 10.1245/ASO.2006.08.035
  contributor:
    fullname: Kimata
– volume: 10
  start-page: 292
  year: 2003
  ident: B89
  article-title: ICP34.5 Deleted Herpes Simplex Virus With Enhanced Oncolytic, Immune Stimulating, and Anti-Tumour Properties
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3301885
  contributor:
    fullname: Liu
– volume: 12
  start-page: 2555
  year: 2006
  ident: B55
  article-title: A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-05-2038
  contributor:
    fullname: Laurie
– volume: 18
  year: 2010
  ident: B51
  article-title: A Phase I Study of Telomerase-Specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors
  publication-title: Mol Ther J Am Soc Gene Ther
  doi: 10.1038/mt.2009.262
  contributor:
    fullname: Nemunaitis
– volume: 7
  year: 2012
  ident: B64
  article-title: Oncolytic Newcastle Disease Virus for Cancer Therapy: Old Challenges and New Directions
  publication-title: Future Microbiol
  doi: 10.2217/fmb.12.4
  contributor:
    fullname: Zamarin
– volume: 71
  start-page: 7
  year: 2021
  ident: B2
  article-title: Cancer Statistics 2021
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21654
  contributor:
    fullname: Siegel
– volume: 60
  start-page: 6359
  year: 2000
  ident: B81
  article-title: Selective Replication and Oncolysis in P53 Mutant Tumors With ONYX-015, an E1B-55kd Gene-Deleted Adenovirus, in Patients With Advanced Head and Neck Cancer: A Phase II Trial
  publication-title: Cancer Res
  contributor:
    fullname: Nemunaitis
– volume: 30
  start-page: 658
  year: 2012
  ident: B9
  article-title: Oncolytic Virotherapy
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.2287
  contributor:
    fullname: Russell
– volume: 6
  year: 2015
  ident: B46
  article-title: Immunological Data From Cancer Patients Treated With Ad5/3-E2F-Δ24-GMCSF Suggests Utility for Tumor Immunotherapy
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.2901
  contributor:
    fullname: Hemminki
– volume: 6
  year: 2010
  ident: B91
  article-title: OPTIM Trial: A Phase III Trial of an Oncolytic Herpes Virus Encoding GM-CSF for Unresectable Stage III or IV Melanoma
  publication-title: Future Oncol
  doi: 10.2217/fon.10.66
  contributor:
    fullname: Kaufman
– volume: 80
  start-page: GS3
  year: 2020
  ident: B18
  article-title: Abstract GS3-04: Pathologic Complete Response (pCR) to Neoadjuvant Treatment With or Without Atezolizumab in Triple Negative, Early High-Risk and Locally Advanced Breast Cancer. NeoTRIPaPDL1 Michelangelo Randomized Study
  publication-title: Cancer Res
  doi: 10.1158/1538-7445.Sabcs19-gs3-04
  contributor:
    fullname: Gianni
– volume: 5
  start-page: e1078057
  year: 2016
  ident: B45
  article-title: Oncolytic Virotherapy for Treatment of Breast Cancer, Including Triple-Negative Breast Cancer
  publication-title: OncoImmunology
  doi: 10.1080/2162402X.2015.1078057
  contributor:
    fullname: Bramante
– volume: 12
  year: 2005
  ident: B84
  article-title: Functional Interactions of Antiapoptotic Proteins and Tumor Necrosis Factor in the Context of a Replication-Competent Adenovirus
  publication-title: Gene Ther
  doi: 10.1038/sj.gt.3302555
  contributor:
    fullname: Liu
– volume: 10
  start-page: 144
  year: 2018
  ident: B26
  article-title: Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro
  publication-title: Cancers
  doi: 10.3390/cancers10050144
  contributor:
    fullname: Garza-Morales
– volume: 167
  year: 2018
  ident: B43
  article-title: A Randomized Phase II Study of Weekly Paclitaxel With or Without Pelareorep in Patients With Metastatic Breast Cancer: Final Analysis of Canadian Cancer Trials Group IND.213
  publication-title: Breast Cancer Res Treat
  doi: 10.1007/s10549-017-4538-4
  contributor:
    fullname: Bernstein
– volume: 18
  start-page: 192
  year: 2018
  ident: B60
  article-title: Oncolytic Virotherapy for Breast Cancer Treatment
  publication-title: Curr Gene Ther
  doi: 10.2174/1566523218666180910163805
  contributor:
    fullname: O'bryan
– volume: 3
  year: 2017
  ident: B33
  article-title: Oncolytic Viruses in Cancer Treatment: A Review
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2016.2064
  contributor:
    fullname: Lawler
– volume: 14
  start-page: 885
  year: 2007
  ident: B53
  article-title: A Phase I Trial of Intravenous Infusion of ONYX-015 and Enbrel in Solid Tumor Patients
  publication-title: Cancer Gene Ther
  doi: 10.1038/sj.cgt.7701080
  contributor:
    fullname: Nemunaitis
– volume-title: Breast Cancer Facts & 017-2018
  year: 2017
  ident: B1
  contributor:
    fullname: Society
– volume: 19
  year: 2013
  ident: B44
  article-title: Antiviral and Antitumor T-Cell Immunity in Patients Treated With GM-CSF–Coding Oncolytic Adenovirus
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-12-2546
  contributor:
    fullname: Kanerva
– volume: 16
  year: 2008
  ident: B72
  article-title: Vaccinia Virus Morphogenesis and Dissemination
  publication-title: Trends Microbiol
  doi: 10.1016/j.tim.2008.07.009
  contributor:
    fullname: Roberts
– volume: 10
  start-page: 5299
  year: 2004
  ident: B76
  article-title: Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-0349-03
  contributor:
    fullname: Chu
– volume: 389
  year: 2017
  ident: B12
  article-title: Breast Cancer
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)31891-8
  contributor:
    fullname: Harbeck
– volume: 2
  start-page: 938
  year: 2002
  ident: B31
  article-title: Oncolytic Viruses
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc948
  contributor:
    fullname: Antonio Chiocca
– volume: 105
  year: 2000
  ident: B77
  article-title: Replication-Selective Adenoviruses as Oncolytic Agents
  publication-title: J Clin Invest
  doi: 10.1172/JCI9762
  contributor:
    fullname: Heise
– volume: 23
  year: 2015
  ident: B40
  article-title: First-In-Man Study of Western Reserve Strain Oncolytic Vaccinia Virus: Safety, Systemic Spread, and Antitumor Activity
  publication-title: Mol Ther J Am Soc Gene Ther
  doi: 10.1038/mt.2014.194
  contributor:
    fullname: Zeh
– volume: 33
  year: 2015
  ident: B37
  article-title: Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2014.58.3377
  contributor:
    fullname: Andtbacka
– volume: 15
  start-page: 115
  year: 2007
  ident: B75
  article-title: Oncolytic Virotherapy for Ovarian Carcinomatosis Using a Replication-Selective Vaccinia Virus Armed With a Yeast Cytosine Deaminase Gene
  publication-title: Cancer Gene Ther
  doi: 10.1038/sj.cgt.7701110
  contributor:
    fullname: Chalikonda
– volume: 14
  start-page: 559
  year: 2014
  ident: B35
  article-title: Going Viral With Cancer Immunotherapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3770
  contributor:
    fullname: Lichty
– volume: 16
  year: 2010
  ident: B50
  article-title: Oncolytic Adenovirus ICOVIR-7 in Patients With Advanced and Refractory Solid Tumors
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-3167
  contributor:
    fullname: Nokisalmi
– volume: 11
  year: 1999
  ident: B82
  article-title: Immune Responses to Adenoviruses: Viral Evasion Mechanisms and Their Implications for the Clinic
  publication-title: Curr Opin Immunol
  doi: 10.1016/S0952-7915(99)80064-8
  contributor:
    fullname: Wold
– volume: 62
  start-page: jnumed.121.262485
  year: 2021
  ident: B29
  article-title: CD8-Targeted PET Imaging of Tumor Infiltrating T Cells in Patients With Cancer: A Phase I First-In-Human Study of 89Zr-Df-IAB22M2C, a Radiolabeled Anti-CD8 Minibody
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.121.262485
  contributor:
    fullname: Farwell
– volume: 18
  year: 2020
  ident: B14
  article-title: Role of Immunotherapy in Triple-Negative Breast Cancer
  publication-title: J Natl Compr Cancer Network J Natl Compr Canc Netw
  doi: 10.6004/jnccn.2020.7554
  contributor:
    fullname: Keenan
– volume: 63
  start-page: 7321
  year: 2003
  ident: B88
  article-title: A Broadly Applicable, Personalized Heat Shock Protein-Mediated Oncolytic Tumor Vaccine
  publication-title: Cancer Res
  contributor:
    fullname: Huang
– start-page: 273
  volume-title: Viral Proteins Counteracting Host Defenses
  year: 2002
  ident: B85
  article-title: Subversion of Host Defense Mechanisms by Adenoviruses
  doi: 10.1007/978-3-642-59421-2_16
  contributor:
    fullname: Burgert
– volume: 70
  year: 2010
  ident: B47
  article-title: Oncolytic Adenovirus Coding for Granulocyte Macrophage Colony-Stimulating Factor Induces Antitumoral Immunity in Cancer Patients
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-09-3567
  contributor:
    fullname: Cerullo
– volume: 14
  start-page: 642
  year: 2015
  ident: B36
  article-title: Oncolytic Viruses: A New Class of Immunotherapy Drugs
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd4663
  contributor:
    fullname: Kaufman
– volume: 20
  year: 2002
  ident: B54
  article-title: Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2002.08.042
  contributor:
    fullname: Pecora
– volume: 72
  year: 2012
  ident: B30
  article-title: Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical Trials
  publication-title: Geburtshilfe und Frauenheilkunde
  doi: 10.1055/s-0031-1298281
  contributor:
    fullname: Hartkopf
– volume: 13
  start-page: 1128
  year: 2021
  ident: B92
  article-title: Oncolytic Virotherapy Treatment of Breast Cancer: Barriers and Recent Advances
  publication-title: Viruses
  doi: 10.3390/v13061128
  contributor:
    fullname: Kwan
– volume: 130
  year: 2012
  ident: B49
  article-title: Integrin Targeted Oncolytic Adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for Treatment of Patients With Advanced Chemotherapy Refractory Solid Tumors
  publication-title: Int J Cancer
  doi: 10.1002/ijc.26216
  contributor:
    fullname: Pesonen
– volume: 28
  year: 2007
  ident: B39
  article-title: Viruses as Anticancer Drugs
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2007.05.005
  contributor:
    fullname: Russell
– volume: 184
  start-page: 71
  year: 2014
  ident: B65
  article-title: Newcastle Disease Virus: Current Status and Our Understanding
  publication-title: Virus Res
  doi: 10.1016/j.virusres.2014.02.016
  contributor:
    fullname: Ganar
– volume: 22
  start-page: 499
  year: 2021
  ident: B15
  article-title: Pembrolizumab Versus Investigator-Choice Chemotherapy for Metastatic Triple-Negative Breast Cancer (KEYNOTE-119): A Randomised, Open-Label, Phase 3 Trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(20)30754-3
  contributor:
    fullname: Winer
– volume: 396
  year: 2020
  ident: B17
  article-title: Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)32531-9
  contributor:
    fullname: Cortes
– volume: 6
  year: 2015
  ident: B78
  article-title: Going Viral: A Review of Replication-Selective Oncolytic Adenoviruses
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.5116
  contributor:
    fullname: Larson
– volume: 19
  year: 2000
  ident: B66
  article-title: Newcastle Disease and Other Avian Paramyxoviruses
  publication-title: Rev Scientifique Technique-Office Int Des Epizooties
  doi: 10.20506/rst.19.2.1231
  contributor:
    fullname: Alexander
– volume: 372
  year: 2015
  ident: B6
  article-title: Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
  publication-title: N Eng J Med
  doi: 10.1056/NEJMoa1413513
  contributor:
    fullname: Swain
– volume: 168
  year: 2017
  ident: B22
  article-title: Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
  publication-title: Cell
  doi: 10.1016/j.cell.2017.01.017
  contributor:
    fullname: Sharma
– volume: 12
  start-page: 252
  year: 2012
  ident: B8
  article-title: The Blockade of Immune Checkpoints in Cancer Immunotherapy
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc3239
  contributor:
    fullname: Pardoll
– volume: 9
  year: 2007
  ident: B70
  article-title: Determination and Analysis of the DNA Sequence of Highly Attenuated Herpes Simplex Virus Type 1 Mutant HF10, a Potential Oncolytic Virus
  publication-title: Microbes Infection
  doi: 10.1016/j.micinf.2006.10.019
  contributor:
    fullname: Ushijima
– volume: 130
  year: 2013
  ident: B94
  article-title: Enhanced Killing of Ovarian Carcinoma Using Oncolytic Measles Vaccine Virus Armed With a Yeast Cytosine Deaminase and Uracil Phosphoribosyltransferase
  publication-title: Gynecologic Oncol
  doi: 10.1016/j.ygyno.2013.05.004
  contributor:
    fullname: Hartkopf
– volume: 19
  start-page: 2
  year: 2000
  ident: B87
  article-title: A Mutant Oncolytic Adenovirus Targeting the Rb Pathway Produces Anti-Glioma Effect In Vivo
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1203251
  contributor:
    fullname: Fueyo
– volume: 8
  start-page: e001486
  year: 2020
  ident: B93
  article-title: Clinical Landscape of Oncolytic Virus Research in 2020
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2020-001486
  contributor:
    fullname: Macedo
– volume: 252
  start-page: 854
  year: 1991
  ident: B32
  article-title: Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
  publication-title: Science
  doi: 10.1126/science.1851332
  contributor:
    fullname: Martuza
– volume: 170
  start-page: 1109
  year: 2017
  ident: B24
  article-title: Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
  publication-title: Cell
  doi: 10.1016/j.cell.2017.08.027
  contributor:
    fullname: Ribas
– volume: 2
  start-page: 295
  year: 2014
  ident: B34
  article-title: Oncolytic Viruses and Their Application to Cancer Immunotherapy
  publication-title: Cancer Immunol Res
  doi: 10.1158/2326-6066.CIR-14-0015
  contributor:
    fullname: Chiocca
– volume: 7
  year: 2007
  ident: B57
  article-title: Clinical Experiment of Mutant Herpes Simplex Virus HF10 Therapy for Cancer
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/156800907780058808
  contributor:
    fullname: Nakao
– volume: 234
  year: 2019
  ident: B61
  article-title: The Viral Approach to Breast Cancer Immunotherapy
  publication-title: Jounal Cell Physiol
  doi: 10.1002/jcp.27150
  contributor:
    fullname: Arab
– volume: 83
  year: 2002
  ident: B71
  article-title: The Formation and Function of Extracellular Enveloped Vaccinia Virus
  publication-title: J Gen Virol
  doi: 10.1099/0022-1317-83-12-2915
  contributor:
    fullname: Smith
– volume: 33
  year: 2015
  ident: B68
  article-title: The Oncolytic Virus, Pelareorep, as a Novel Anticancer Agent: A Review
  publication-title: Investigational New Drugs
  doi: 10.1007/s10637-015-0216-8
  contributor:
    fullname: Chakrabarty
– volume: 379
  year: 2018
  ident: B16
  article-title: Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
  publication-title: New Eng J Med
  doi: 10.1056/NEJMoa1809615
  contributor:
    fullname: Schmid
– volume: 16
  start-page: 1441
  year: 2009
  ident: B79
  article-title: A Modified E2F-1 Promoter Improves the Efficacy to Toxicity Ratio of Oncolytic Adenoviruses
  publication-title: Gene Ther
  doi: 10.1038/gt.2009.103
  contributor:
    fullname: Rojas
– volume: 28
  year: 2010
  ident: B41
  article-title: Intravenous Administration of Reolysin, a Live Replication Competent RNA Virus Is Safe in Patients With Advanced Solid Tumors
  publication-title: Investigational New Drugs
  doi: 10.1007/s10637-009-9279-8
  contributor:
    fullname: Gollamudi
– volume: 16
  start-page: 376
  year: 2008
  ident: B52
  article-title: A Phase I Trial of Intratumoral Administration of Recombinant Oncolytic Adenovirus Overexpressing HSP70 in Advanced Solid Tumor Patients
  publication-title: Gene Ther
  doi: 10.1038/gt.2008.179
  contributor:
    fullname: Li
– volume: 32
  start-page: 994
  year: 2021
  ident: B20
  article-title: Primary Results From IMpassion131, a Double-Blind, Placebo-Controlled, Randomised Phase III Trial of First-Line Paclitaxel With or Without Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2021.05.801
  contributor:
    fullname: Miles
– volume: 197
  year: 1993
  ident: B69
  article-title: Evidence That the Epidermal Growth Factor Receptor on Host Cells Confers Reovirus Infection Efficiency
  publication-title: Virology
  doi: 10.1006/viro.1993.1602
  contributor:
    fullname: Strong
– volume: 89
  start-page: 799
  year: 2007
  ident: B90
  article-title: The dsRNA Protein Kinase PKR: Virus and Cell Control
  publication-title: Biochimie
  doi: 10.1016/j.biochi.2007.03.001
  contributor:
    fullname: García
– volume: 28
  year: 2021
  ident: B63
  article-title: Viroimmunotherapy for Breast Cancer: Promises, Problems and Future Directions
  publication-title: Cancer Gene Ther
  doi: 10.1038/s41417-020-00265-6
  contributor:
    fullname: Chaurasiya
– volume: 10
  year: 2001
  ident: B80
  article-title: Telomerase and Cancer
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/10.7.677
  contributor:
    fullname: Shay
– volume: 19
  year: 2012
  ident: B58
  article-title: Impact of Novel Oncolytic Virus HF10 on Cellular Components of the Tumor Microenviroment in Patients With Recurrent Breast Cancer
  publication-title: Cancer Gene Ther
  doi: 10.1038/cgt.2011.80
  contributor:
    fullname: Sahin
– volume: 382
  year: 2020
  ident: B19
  article-title: Pembrolizumab for Early Triple-Negative Breast Cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1910549
  contributor:
    fullname: Schmid
– volume: 123
  year: 2011
  ident: B10
  article-title: Oncolytic Virotherapy of Breast Cancer
  publication-title: Gynecologic Oncol
  doi: 10.1016/j.ygyno.2011.06.021
  contributor:
    fullname: Hartkopf
– volume: 14
  year: 2020
  ident: B62
  article-title: Oncolytic Virotherapy: New Weapon for Breast Cancer Treatment
  publication-title: Ecancermedicalscience
  doi: 10.3332/ecancer.2020.1149
  contributor:
    fullname: Martini
– volume: 9
  start-page: 1729300
  year: 2020
  ident: B27
  article-title: Oncolytic Poxvirus CF33-hNIS-ΔF14.5 Favorably Modulates Tumor Immune Microenvironment and Works Synergistically With Anti-PD-L1 Antibody in a Triple-Negative Breast Cancer Model
  publication-title: OncoImmunology
  doi: 10.1080/2162402X.2020.1729300
  contributor:
    fullname: Chaurasiya
– volume: 381
  year: 2019
  ident: B5
  article-title: Overall Survival With Ribociclib Plus Endocrine Therapy in Breast Cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1903765
  contributor:
    fullname: Im
– volume: 3
  year: 2001
  ident: B83
  article-title: Tnfα and Ifnγ Induced by Innate Anti-Adenoviral Immune Responses Inhibit Adenovirus-Mediated Transgene Expression
  publication-title: Mol Ther
  doi: 10.1006/mthe.2001.0318
  contributor:
    fullname: Sung
– volume: 8
  start-page: 61
  year: 2005
  ident: B86
  article-title: Heat Shock Phenocopies E1B-55K Late Functions and Selectively Sensitizes Refractory Tumor Cells to ONYX-015 Oncolytic Viral Therapy
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2005.06.009
  contributor:
    fullname: O’shea
– volume: 4
  start-page: 39
  year: 2015
  ident: B11
  article-title: Chemovirotherapy: Combining Chemotherapeutic Treatment With Oncolytic Virotherapy
  publication-title: Oncolytic Virotherapy
  doi: 10.2147/OV.S54780
  contributor:
    fullname: Binz
– volume: 6
  start-page: 821
  year: 2000
  ident: B67
  article-title: Exploiting Tumor-Specific Defects in the Interferon Pathway With a Previously Unknown Oncolytic Virus
  publication-title: Nat Med
  doi: 10.1038/77558
  contributor:
    fullname: Stojdl
– volume: 31
  start-page: 696
  year: 2013
  ident: B42
  article-title: REO-001: A Phase I Trial of Percutaneous Intralesional Administration of Reovirus Type 3 Dearing (Reolysin®) in Patients With Advanced Solid Tumors
  publication-title: Investigational New Drugs
  doi: 10.1007/s10637-012-9865-z
  contributor:
    fullname: Morris
– volume: 4
  year: 2018
  ident: B21
  article-title: Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2017.4445
  contributor:
    fullname: Ben-Aharon
– volume: 14
  year: 2013
  ident: B3
  article-title: Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA Study): Overall Survival Results From a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(13)70130-X
  contributor:
    fullname: Swain
– volume: 9
  start-page: 71
  year: 2021
  ident: B28
  article-title: Oncolytic Viruses for Triple Negative Breast Cancer and Beyond
  publication-title: Biomark Res
  doi: 10.1186/s40364-021-00318-4
  contributor:
    fullname: Jin
– volume: 11
  year: 2016
  ident: B13
  article-title: PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
  publication-title: Breast Care (Basel Switzerland)
  doi: 10.1159/000453569
  contributor:
    fullname: Hartkopf
– volume: 61
  start-page: 8751
  year: 2001
  ident: B74
  article-title: Systemic Cancer Therapy With a Tumor-Selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes
  publication-title: Cancer Res
  contributor:
    fullname: Mccart
– volume: 379
  year: 2018
  ident: B4
  article-title: Overall Survival With Palbociclib and Fulvestrant in Advanced Breast Cancer
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1810527
  contributor:
    fullname: Turner
– volume: 8
  start-page: e000465
  year: 2020
  ident: B25
  article-title: Oncolytic Vesicular Stomatitis Virus-Based Cellular Vaccine Improves Triple-Negative Breast Cancer Outcome by Enhancing Natural Killer and CD8(+) T-Cell Functionality
  publication-title: J Immunother Cancer
  doi: 10.1136/jitc-2019-000465
  contributor:
    fullname: Niavarani
– volume: 76
  year: 2016
  ident: B38
  article-title: Talimogene Laherparepvec: First Global Approval
  publication-title: Drugs
  doi: 10.1007/s40265-015-0522-7
  contributor:
    fullname: Greig
– volume: 19
  year: 2011
  ident: B48
  article-title: Immunological Effects of Low-Dose Cyclophosphamide in Cancer Patients Treated With Oncolytic Adenovirus
  publication-title: Mol Ther
  doi: 10.1038/mt.2011.113
  contributor:
    fullname: Cerullo
SSID ssj0000650103
Score 2.3852978
SecondaryResourceType review_article
Snippet Breast cancer is the second most common kind of cancer worldwide and oncolytic viruses may offer a new treatment approach. There are three different types of...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 803050
SubjectTerms breast cancer
clinical trials
Oncology
oncolytic virus
review
virotherapy
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LSxxBEG5kD-IlRONjooYO5OJh3On39FElIgGTy654a_qJCzIb9nHIv0_X9Ci7QfCS6zzo4vtququmiq8Q-pZar5SVolbSsZoT7-q21bYmNHpGmRQkwg_9-5_ybsp_PIrHjVFf0BNW5IELcGNPkmtY5I76hqvEnfQ2KBIYDI1pSAmNiNhIpsoeLGCAQalL5ixMj9O8A8VCSi5b8PFm6xzq5frfijH_bZXcOHtuP6IPQ9CIr4qx-2gndgdo934oi39CYlD3fMaT3p_wPOFfXab4T34BP8wW62Vc4lmHr6EFfYVvgOrFIZrefp_c3NXDPITac0lXtbRaBMss5SJyGrwIPsT8ATnuiLZCO--SpUmExusmwXCpDFRyUifiqaKBHaFRN-_iCcIuSJq4p6FJiYvUWh9AaS9y3kQuhK3QxQs65neRvTA5XQAkDSBpAElTkKzQNcD3-hwIVvcXMo1moNG8R2OFvr6Ab7KDQ9XCdnG-Xpqc4oGqHlWyQseFjNelmOglBdsKqS2atmzZvtPNnnoR7VYxJrT-_D-MP0V7gAd0uVB2hkarxTqe51hl5b70bvkX8MXnng
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NT9tAEF1VICEuiLa0BNpqK_XCwam9n_YBoSYCoUopl6TittpPiBTZ4CQS_Ht2bAcIyomr7dWu3rz1zHjWbxD6FXIrpRY8kcLQhGXWJHle6CQj3lJCBc88fNAf_ROXE_b3ml-__B7dATjfmNpBP6lJPes_3D-exQ1_Chln9Le_Q1WCGCHJ-jnQNybw24RRBnwfdcF--17m0NSgrVVuHLiLdihvROryNTfVqPlvCkHfnqR85Zou9tFeF1PiPy0JPqIPvvyEdkZd1fwz4p345wyPG7rhKuCrMjLgMQ7A_6f1cu7neFriAZxQX-AhMKE-QJOL8_HwMunaJSSWCbJIhC6401QTxj0jznJnnY_7yzCTFZoXxpqgSeAutUUaoPeUk1kwogiZJZI4-gVtlVXpDxE2TpDALHFpCIyHXFsHQnyesdQzznUPnazQUXetKoaK2QSAqgBUBaCqFtQeGgB8z8-BnnVzoapvVLc9lI0LSalnhtiUycCMsDquzlFoDZRmccKfK_BV5D8UNXTpq-VcxQwQRPeIFD30tTXG81QrY_aQXDPT2lrW75TT20ZjO5eU8qI4evfIY7QLIMDJF0K_oa1FvfTfY_yyMD8aWj4B76_vlw
  priority: 102
  providerName: Scholars Portal
Title Clinical Trials of Oncolytic Viruses in Breast Cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/35004328
https://search.proquest.com/docview/2618506276
https://pubmed.ncbi.nlm.nih.gov/PMC8733599
https://doaj.org/article/c1fb03e4b2c047f4b6cad71d3627401a
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELbaHhAXxJttoTISFw7ZTfyMj3RFqZAWOLRob5afsFLrVPs48O_rcZKqizhxsaIklkffTOKZzOQbhD7E1klpBK-ksLRijbNV2ypTNSQ4SqjgTYAP-otv4uKKfV3y5QHi478wpWjf2dU0Xd9M0-p3qa28vXGzsU5s9mMxbyWlXKnZITrMRw9C9P71y6F3QZ-SzAGYmsUuAVkhaaYtmDc0f6O8cNG1e7tRIe3_l6f5d8Hkgx3o_Cl6MriO-FMv4jN0ENJz9GgxJMdfID5wfF7jy2JVuIv4e8qK_pMn4J-r9W4TNniV8BkUom_xHBS-fomuzj9fzi-qoStC5Zgg20oYxb2hhjAeGPGOe-dDfowss40yXFlnoyGR-9qpOkKLKS-baIWKjSOSePoKHaUuhTcIWy9IZI74OkbGY2ucB769wFgdGOdmgj6O6OjbnvxC56ABQNUAqgZQdQ_qBJ0BfPf3AW11OdGtf-lBedplQWoamCWuZjIyK5zJ0nkKHYDqJi_4fgRfZzOH3IVJodttdA70gFuPSDFBr3tl3C81KnOC5J6a9mTZv5Itq1BpD5Z0_N8zT9BjAAEKXAh9i4626114l92UrT0t4X0evyybPC5Ye1oM9Q7KAOqi
link.rule.ids 230,315,733,786,790,870,891,2115,24346,27957,27958,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEB6VIkEvvCnhaSQuHJzY-7SPNKIK0BQOadXbap8Q0dpV4hzg17PjR9VUXODq9WrH8816d7yfvwF4FworpRY8lcLQlOXWpEVR6jQn3lJCBc89ftCfH4vZCft8xs92gA__wrSkfWuW4-r8Ylwtf7TcyssLOxl4YpNv82khKeVlObkFt-N8JfJakt69gDlWL-gOJWMKVk5CXaFcIcnHBQY4ln-jvFWjK7bWo1a2_297zZuUyWtr0OF9OB2s76gnP8ebxozt7xvCjv_8eA_gXr8rTT50zQ9hx1eP4M68P3d_DLyXDz1PFm3AJnVIvlYxhn7FDsnpcrVZ-3WyrJID5Lg3yRRjafUETg4_LqaztC-4kFomSJMKXXKnqSaMe0ac5c46H2eoYSYvNS-NNUGTwF1myyxg9Son82BEGXJLJHH0KexWdeWfQWKcIIFZ4rIQGA-Ftg6l_DxjmWec6xG8H9yuLjtdDRXzEURLIVoK0VIdWiM4QFyu7kNF7PZCvfquescpGw3JqGeG2IzJwIywOlrnKBYXyvI44NsBVRVnEB6L6MrXm7WKOSTK9hEpRrDfoXw11BAlI5Bb-G_Zst0SUW1VunsUn_93zzdwd7aYH6mjT8dfXsAeOgR5NIS-hN1mtfGv4m6oMa_b2P8D5f8J9Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1JbxMxGLWgSBUX9iWsg8SFw2xex0caiMqS0kOLKi6WV4hoZ6JkcoBfj79ZqqTi1OuMLS_veexv_PQ-hN6GygqhOUsFNySlpTVpVUmdlthbgglnpYcf-vMjfnhKP5-xs61UX51o35pFVp9fZPXiV6etXF7YfNSJ5cfzaSUIYVLmSxfym-hWXLNYbgXq_UeYQQaD_mIyhmEyD00NloW4zCogOaSAI6xzpKt29qTOuv9_582rssmtfWh2F_0YR9DLT35nm9Zk9u8Vc8drDfEeujOcTpP3fZH76IavH6D9-XD__hCxwUb0PDnpiJs0IflWRy79iRWS74vVZu3XyaJODkDr3iZT4NTqETqdfTyZHqZD4oXUUo7blGvJnCYaU-YpdpY563xcqYaaUmomjTVB48BcYWURIIuVE2UwXIbSYoEdeYz26qb2T1FiHMeBWuyKECgLlbYOLP08pYWnjOkJejdOvVr2_hoqxiWAmALEFCCmesQm6ACwuSwHztjdg2b1Uw2Tp2zsSEE8NdgWVARquNWxd45AkqGijA2-GZFVcSXB9YiufbNZqxhLgn0fFnyCnvRIXzY1MmWCxA4Hdvqy-yYi27l1D0g-u3bN12j_-MNMff109OU5ug3zAXIaTF6gvXa18S_joag1rzr6_wM9agx1
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+Trials+of+Oncolytic+Viruses+in+Breast+Cancer&rft.jtitle=Frontiers+in+oncology&rft.au=Carter%2C+Mary+E.&rft.au=Koch%2C+Andr%C3%A9&rft.au=Lauer%2C+Ulrich+M.&rft.au=Hartkopf%2C+Andreas+D.&rft.date=2021-12-23&rft.pub=Frontiers+Media+S.A&rft.eissn=2234-943X&rft.volume=11&rft_id=info:doi/10.3389%2Ffonc.2021.803050&rft_id=info%3Apmid%2F35004328&rft.externalDBID=PMC8733599
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2234-943X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2234-943X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2234-943X&client=summon